Edward Nash
Stock Analyst at Canaccord Genuity
(3.89)
# 684
Out of 4,711 analysts
71
Total ratings
51.61%
Success rate
10.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $47.71 | +86.54% | 1 | Nov 25, 2024 | |
| VRNA Verona Pharma | Maintains: Buy | $37 → $44 | $42.02 | +4.71% | 8 | Nov 5, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $22 | $17.18 | +28.06% | 8 | Sep 30, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.24 | +525.00% | 6 | Aug 12, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $38 → $78 | $51.40 | +51.75% | 5 | Jul 31, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.28 | +525.00% | 3 | May 23, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $59 → $56 | $29.34 | +90.87% | 5 | May 13, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.35 | +751.06% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $1.40 | +542.86% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $308.44 | +22.23% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $1.79 | +346.93% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.39 | +287.24% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.21 | +263.36% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.37 | -15.61% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $3.05 | +5,801.64% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $44.22 | +85.44% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.74 | +1,587.76% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $16.98 | +182.69% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.70 | +11,303.51% | 1 | Nov 8, 2017 |
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $47.71
Upside: +86.54%
Verona Pharma
Nov 5, 2024
Maintains: Buy
Price Target: $37 → $44
Current: $42.02
Upside: +4.71%
Travere Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $17.18
Upside: +28.06%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.24
Upside: +525.00%
Corcept Therapeutics
Jul 31, 2024
Maintains: Buy
Price Target: $38 → $78
Current: $51.40
Upside: +51.75%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.28
Upside: +525.00%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59 → $56
Current: $29.34
Upside: +90.87%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.35
Upside: +751.06%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $1.40
Upside: +542.86%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $308.44
Upside: +22.23%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.79
Upside: +346.93%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.39
Upside: +287.24%
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $13.21
Upside: +263.36%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.37
Upside: -15.61%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $3.05
Upside: +5,801.64%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $44.22
Upside: +85.44%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.74
Upside: +1,587.76%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $16.98
Upside: +182.69%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.70
Upside: +11,303.51%